TTYH2

Across TCGA pan-cancer cohorts, TTYH2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TTYH2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher TTYH2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTYH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, LIHC, and UCEC are the cancer types where TTYH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
LIHC	OS	Median	All	0.181	0.779	<.001	15	view →
UCEC	OS	Median	II,III,IV	0.937	0.319	.015	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TTYH2–DLBC (OS)

Open the DLBC breakdown →